10-Q: Tevogen Bio Holdings Inc. Reports Third Quarter 2024 Financial Results, Cites Progress in T-Cell Therapy Development

Tevogen Bio Holdings Inc. reported its financial results for the third quarter ended September 30, 2024, highlighting ongoing research and development efforts in T-cell therapy.

Summary

• Tevogen Bio Holdings Inc. reported a net loss of $5.9 million for the three months ended September 30, 2024, and a net loss of $4.3 million for the nine months ended September 30, 2024.
• The company's operating expenses totaled $6.1 million for the quarter and $44.2 million for the nine-month period, with significant investments in research and development.
• Research and development expenses were $3.3 million for the quarter and $28.2 million for the nine-month period, reflecting the company's focus on advancing its T-cell therapy programs.
• General and administrative expenses were $2.8 million for the quarter and $16.0 million for the nine-month period, including costs associated with the recent merger and stock-based compensation.
• The company had cash of $2.3 million as of September 30, 2024, and has secured additional funding through preferred stock sales and a loan agreement.
• Tevogen Bio is a clinical-stage immunotherapy company focused on developing off-the-shelf T-cell therapies for infectious diseases and cancers.
• The company's lead product candidate, TVGN 489, is in development for the treatment of COVID-19 and Long COVID, with a Phase 1 trial completed.
• The company has a loan agreement in place that allows for monthly drawdowns of $1 million for 36 months, totaling $36 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and funding, the significant net losses, ongoing operational costs, and the default on notes payable, and material weaknesses in internal control over financial reporting, temper the overall sentiment.

Positives

• Tevogen Bio has completed a Phase 1 proof-of-concept trial for TVGN 489, showing promising results.
• The company has secured a loan agreement providing access to $36 million in funding.
• Tevogen Bio has a growing intellectual property portfolio, including three issued U.S. patents.
• The company has received $2 million from the sale of Series C Preferred Stock subsequent to September 30, 2024.
• The company has regained compliance with the Nasdaq minimum bid price requirement.

Negatives

• Tevogen Bio reported a net loss of $5.9 million for the third quarter of 2024.
• The company has incurred significant operating expenses, particularly in research and development.
• The company is in default of its obligations under notes payable to Polar Multi-Strategy Master Fund.
• The company has a history of losses and negative cash flows from operations since inception.
• The company's disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this report due to material weaknesses in internal control over financial reporting.

Risks

• The company has a limited operating history and has not generated any revenue to date.
• Tevogen Bio is subject to risks associated with any specialty biotechnology company that requires considerable expenditures for research and development.
• The company's research and development projects may not be successful, products developed may not obtain necessary regulatory approval, and any approved product may not be commercially viable.
• The company may not be able to obtain financing on acceptable terms, which could adversely affect its business prospects.
• The company is dependent on the services of its employees and consultants.
• The company is in default of its obligations under notes payable to Polar Multi-Strategy Master Fund.
• The company's disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this report due to material weaknesses in internal control over financial reporting.
• The company has previously failed to timely file certain periodic reports with the SEC.

Future Outlook

The company plans to launch a pivotal trial of TVGN 489 in COVID-19 patients with B cell malignancies, with studies of other highly vulnerable populations thereafter. The company also plans to expand its research and development capability, build its manufacturing infrastructure, and develop its commercialization organization. The company expects to incur increased costs associated with operating as a public company.

Management Comments

• Management believes that cash of $2,330,681 as of September 30, 2024, the $2,000,000 received for the sale of Series C Preferred Stock subsequent to September 30, 2024, and the Loan Agreement entered into in June 2024, will allow the Company to have adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these unaudited consolidated financial statements.
• Management regularly evaluates different strategies to obtain funding for operations for subsequent periods.

Industry Context

Tevogen Bio operates in the competitive biotechnology industry, focusing on T-cell therapies, a rapidly evolving field. The company's approach to developing off-the-shelf, precision T-cell therapeutics is aimed at addressing the limitations of existing treatments and making cell therapy more accessible. The company's focus on COVID-19 and Long COVID aligns with the ongoing global health challenges and the need for effective treatments.

Comparison to Industry Standards

• Tevogen Bio's focus on allogeneic, off-the-shelf T-cell therapies differentiates it from companies primarily developing autologous therapies, such as those from Gilead (Yescarta, Tecartus) and Novartis (Kymriah).
• The company's ExacTcell technology, which targets multiple antigens, contrasts with the single-antigen targeting approach of many CAR T-cell therapies.
• The company's Phase 1 trial results for TVGN 489, showing no dose-limiting toxicities and rapid viral load reduction, are comparable to early-stage results from other companies developing novel immunotherapies.
• The company's financial position, with $2.3 million in cash and a $36 million loan agreement, is relatively modest compared to larger, more established biotechnology companies, such as Regeneron or Amgen, which have significantly larger cash reserves and revenue streams.
• The company's operating expenses, particularly in research and development, are typical for a clinical-stage biotechnology company, but the company's net losses are significant, reflecting the high costs of drug development.

Related Party Transactions

• The company has a loan agreement with The Patel Family, LLP, a related party.
• The company incurred fees to the Sponsor for advisory services in connection with the merger.
• The company issued Performance-Based RSUs to the wife of the CEO and to a company controlled by the daughter of the CFO.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, including net losses and the need for additional funding.
• Employees are impacted by the company's ongoing research and development activities and the need to manage growth.
• Customers (potential patients) are impacted by the company's progress in developing new therapies for infectious diseases and cancers.
• Suppliers and creditors are impacted by the company's financial condition and ability to meet its obligations.

Next Steps

• The company plans to launch a pivotal trial of TVGN 489 in COVID-19 patients with B cell malignancies.
• The company will continue pre-clinical development of TVGN 489 for treatment and prevention of Long COVID.
• The company will continue to develop other product candidates in its pipeline.
• The company will continue to evaluate different strategies to obtain funding for operations.

Key Dates

Keywords

Tevogen Bio, T-cell therapy, immunotherapy, TVGN 489, COVID-19, Long COVID, clinical trial, research and development, biotechnology, ExacTcell, preferred stock, loan agreement, Nasdaq, financial results